IP Group (IPO)

Sector:

Financials

Index:

FTSE 250

82.20p
   
  • Change Today:
      3.15p
  • 52 Week High: 155.20
  • 52 Week Low: 77.25
  • Currency: UK Pounds
  • Shares Issued: 1,034.09m
  • Volume: 1,372,815
  • Market Cap: £850.03m
  • RiskGrade: 192

Deal with Barclays    Trade now with Barclays Stockbrokers

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

By Iain Gilbert

Date: Tuesday 19 Oct 2021

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.
Oxford Biomedica stated that under the terms of the option and license agreement, Boehringer Ingelheim will pay it an option exercise fee of £3.5m, while also being entitled to further development, regulatory and sales milestones of up to an additional £27.5m and a "tiered low single-digit royalty" on net sales of the cystic fibrosis gene therapy product.

Boehringer's move follows on from the striking of a development and supply agreement between the pair in April, which covered the clinical manufacture of various types of viral vector-based products.

Elsewhere, the German pharmaceutical group also exercised an option to license intellectual property and know-how from IP Group and the UK Cystic Fibrosis Gene Therapy Consortium in relation to the same lentiviral vector-based product candidate.

As of 0915 BST, Oxford Biomedica shares had inched ahead 0.33% to 1,494.92p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

IP Group Market Data

Currency UK Pounds
Share Price 82.20p
Change Today 3.15p
% Change 3.98 %
52 Week High 155.20
52 Week Low 77.25
Volume 1,372,815
Shares Issued 1,034.09m
Market Cap £850.03m
RiskGrade 192

IP Group Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
74.76% above the market average74.76% above the market average74.76% above the market average74.76% above the market average74.76% above the market average
75.21% above the sector average75.21% above the sector average75.21% above the sector average75.21% above the sector average75.21% above the sector average
Price Trend
29.86% below the market average29.86% below the market average29.86% below the market average29.86% below the market average29.86% below the market average
29.93% below the sector average29.93% below the sector average29.93% below the sector average29.93% below the sector average29.93% below the sector average
Income
31.77% below the market average31.77% below the market average31.77% below the market average31.77% below the market average31.77% below the market average
37.66% below the sector average37.66% below the sector average37.66% below the sector average37.66% below the sector average37.66% below the sector average
Growth
92.86% above the market average92.86% above the market average92.86% above the market average92.86% above the market average92.86% above the market average
86.55% above the sector average86.55% above the sector average86.55% above the sector average86.55% above the sector average86.55% above the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 3
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

IP Group Dividends

  Latest Previous
  Final Interim
Ex-Div 26-May-22 12-Aug-21
Paid 30-Jun-22 27-Sep-21
Amount 0.72p 0.48p

Trades for 20-May-2022

Time Volume / Share Price
17:13 1,180 @ 82.40p
17:13 2,320 @ 82.40p
16:35 218,255 @ 82.20p
16:29 569 @ 82.40p
16:29 1,931 @ 82.40p

IP Group Key Personnel

CEO Greg Smith

Top of Page